Hepatitis B
Prolonged Entecavir for Slow Responders
- Details
- Category: Approved HBV Drugs
- Published on Friday, 03 June 2011 13:11
- Written by Liz Highleyman
Treatment-naive hepatitis B patients who stay on entecavir (Baraclude) monotherapy despite suboptimal response at 48 weeks are likely to go on to achieve undetectable viral load. 
Mothers with Hepatitis B Can Safely Breastfeed
- Details
- Category: Pregnancy & HBV MTCT
- Published on Tuesday, 24 May 2011 07:42
- Written by Liz Highleyman
Women with chronic HBV infection can breastfeed with minimal risk of transmitting the virus to their babies if they use standard prophylactic therapy, according to a recent review.
Switch to Lamivudine Not as Effective as Staying on Entecavir
- Details
- Category: Approved HBV Drugs
- Published on Friday, 06 May 2011 09:14
- Written by James Learned
Hepatitis B patients who switch to cheaper lamivudine (Epivir-HBV) after achieving undetectable HBV viral load and normal ALT on entecavir (Baraclude) are more likely to experience viral rebound. 
Is Hepatitis B Under-treated in U.S.?
- Details
- Category: HBV Treatment
- Published on Friday, 20 May 2011 07:48
- Written by Liz Highleyman
As few as 5% of the approximately 1.4 to 2.0 million people with chronic hepatitis B in the U.S. are tested, enter care, and are successfully treated, according to a recent review. 
HBV Rebound Common in Patients Taking Oral Meds
- Details
- Category: HBV Treatment
- Published on Tuesday, 03 May 2011 09:25
- Written by Wiley-Blackwell
Nearly half of patients taking nucleoside/nucleotide analogs to treat hepatitis B experienced viral breakthrough over 5 years, and about 40% of these were not attributable to drug resistance mutations.
DHHS Releases Viral Hepatitis Action Plan
- Details
- Category: HBV Policy & Advocacy
- Published on Friday, 13 May 2011 15:41
- Written by DHHS
New DHHS report details plan for prevention, care, and treatment of hepatitis B and C. 
Additional HBV Vaccine Dose Offers More Protection for People with HIV
- Details
- Category: HBV Vaccines
- Published on Saturday, 23 April 2011 09:18
- Written by Paul Dalton
Two alternative dosing schedules of hepatitis B virus (HBV) vaccination led to higher levels of protection than the standard 3-dose schedule.
Tenofovir Improves Outcomes of HBV Acute-on-Chronic Liver Failure
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 10 May 2011 09:06
- Written by Liz Highleyman
Treatment with tenofovir (Viread) lowers HBV viral load, reduces liver injury, and decreases the risk of death in patients with acute-on-chronic liver failure due to hepatitis B reactivation.
Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 12 April 2011 03:38
- Written by Liz Highleyman
Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL 2011.
More Articles...
- Telbivudine Label Adds Resistance Warning
- Entecavir Beats Adefovir for Hepatitis B Treatment
- Hepatitis B Vaccination Dramatically Lowers Prevalence among U.S. Children
- Entecavir Approved in Europe for Hepatitis B Patients with Decompensated Liver Diseases
- New Hepatitis B Surface Antigen Test Helps Assess Treatment Response
Web Design and Development by